Synthon Pharmaceuticals’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC
4/2/2014 9:31:05 AM
NIJMEGEN, Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche’s market leading anti-HER2 ADC, T-DM1 ( Kadcyla®*). SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon’s proprietary cleavable linker-duocarmycin (vc-seco-DUBA) payload. Data support the potential of SYD985 to address the high unmet medical need of patients with HER2 2+ and HER2 1+ breast cancer for whom there is currently no effective therapy available.
Help employers find you! Check out all the jobs and post your resume.
comments powered by